BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21151624)

  • 1. Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation.
    Gupta G; Womer KL
    Drug Des Devel Ther; 2010 Dec; 4():375-82. PubMed ID: 21151624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel immunosuppressive agents in kidney transplantation.
    Cooper JE; Wiseman AC
    Clin Nephrol; 2010 May; 73(5):333-43. PubMed ID: 20420793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological agents in kidney transplantation: belatacept is entering the field.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belatacept: a novel immunosuppressive agent for kidney transplant recipients.
    Charpentier B
    Expert Rev Clin Immunol; 2012 Nov; 8(8):719-28. PubMed ID: 23167683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costimulation targeting therapies in organ transplantation.
    Gandhi AM; Fazli U; Rodina V; Qazi YA
    Curr Opin Organ Transplant; 2008 Dec; 13(6):622-6. PubMed ID: 19060553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belatacept in kidney transplantation.
    Wojciechowski D; Vincenti F
    Curr Opin Organ Transplant; 2012 Dec; 17(6):640-7. PubMed ID: 23044530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belatacept in kidney transplantation.
    Satyananda V; Shapiro R
    Curr Opin Organ Transplant; 2014 Dec; 19(6):573-7. PubMed ID: 25333833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for using belatacept in combination with sirolimus.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Transplant Proc; 2010 Nov; 42(9 Suppl):S29-31. PubMed ID: 21095447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belatacept utilization recommendations: an expert position.
    Grinyó JM; Budde K; Citterio F; Charpentier B
    Expert Opin Drug Saf; 2013 Jan; 12(1):111-22. PubMed ID: 23206310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept.
    Martin ST; Powell JT; Patel M; Tsapepas D
    Am J Health Syst Pharm; 2013 Nov; 70(22):1977-83. PubMed ID: 24173007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).
    Durrbach A; Pestana JM; Pearson T; Vincenti F; Garcia VD; Campistol J; Rial Mdel C; Florman S; Block A; Di Russo G; Xing J; Garg P; Grinyó J
    Am J Transplant; 2010 Mar; 10(3):547-57. PubMed ID: 20415898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys.
    Song L; Ma A; Dun H; Hu Y; Fujii Y; Kinugasa F; Oshima S; Higashi Y; Daloze P; Chen H
    Am J Transplant; 2017 Mar; 17(3):635-645. PubMed ID: 27598231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belatacept: the promises and challenges of belatacept and costimulatory blockade.
    Kaplan B
    Am J Transplant; 2010 Mar; 10(3):441-2. PubMed ID: 20415895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
    Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belatacept: a new biologic and its role in kidney transplantation.
    Su VC; Harrison J; Rogers C; Ensom MH
    Ann Pharmacother; 2012 Jan; 46(1):57-67. PubMed ID: 22215686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes.
    Rostaing L; Neumayer HH; Reyes-Acevedo R; Bresnahan B; Florman S; Vitko S; Heifets M; Xing J; Thomas D; Vincenti F
    Clin J Am Soc Nephrol; 2011 Nov; 6(11):2696-704. PubMed ID: 21921152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belatacept: a new era of immunosuppression?
    El-Charabaty E; Geara AS; Ting C; El-Sayegh S; Azzi J
    Expert Rev Clin Immunol; 2012 Aug; 8(6):527-36. PubMed ID: 22992146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
    Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B
    Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belatacept: in adult kidney transplant recipients.
    Garnock-Jones KP
    BioDrugs; 2012 Dec; 26(6):413-24. PubMed ID: 22928660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.